RNF74抗体经ICC, IHC严格验证,品质保证.适用于多种种属反应性,被多篇文献引用并有用户反馈信息.确保特异性!产物具有以下特点:
1、全：网络全世界的上等产物，基本上各种抗体产物在该公司均能找到
2、新：产物及网站更新非常快，基本上每周均有新产物出现
3、优：产物质量好，投诉比较少
4、强：强大的技术支持队伍和力量，网站上有齐全的技术资料以及客户评论，并提供实时在线技术咨询，使您使用产物时没有任何后顾之忧。
产物编号xy-6941R
英文名称搁狈贵74
中文名称环指蛋白74抗体（重组激活基因1）
别 名RAG-1;E3 ubiquitin-protein ligase RAG1; RAG-1; RAG1; RAG1_HUMAN; recombination activating gene 1; recombination activating protein 1; RING finger protein 74; RNF74; V(D)J recombination-activating protein 1.
说 明 书100ul 200ul
研究领域细胞生物 信号转导 **细胞 表观遗传学
抗体来源搁补产产颈迟
克隆类型笔辞濒测肠濒辞苍补濒
RNF74抗体交叉反应 Human, Mouse, Rat, Pig, Sheep,
产物应用WB=1:500-2000 ELISA=1:500-1000 IHC-P=1:400-800 IHC-F=1:400-800 Flow-Cyt=1μg/Test IF=1:100-500 （石蜡切片需做抗原修复）
not yet tested in other applications.
optimal dilutions/concentrations should be determined by the end user.
分 子 量115kDa
细胞定位细胞核
性 状Lyophilized or Liquid
浓 度1mg/1ml
免 疫 原KLH conjugated synthetic peptide derived from human RAG1/RNF74
亚 型IgG
纯化方法affinity purified by Protein A
储 存 液0.01M TBS(pH7.4) with 1% BSA, 0.03% Proclin300 and 50% Glycerol.
保存条件Store at -20 °C for one year. Avoid repeated freeze/thaw cycles. The lyophilized antibody is stable at room temperature for at least one month and for greater than a year when kept at -20°C. When reconstituted in sterile pH 7.4 0.01M PBS or diluent of antibody the antibody is stable for at least two weeks at 2-4 °C.
PubMedPubMed
产物介绍产补肠办驳谤辞耻苍诲:
Catalytic component of the RAG complex, a multiprotein complex that mediates the DNA cleavage phase during V(D)J recombination. V(D)J recombination assembles a diverse repertoire of immunoglobulin and T-cell receptor genes in developing B and T lymphocytes through rearrangement of different V (variable), in some cases D (diversity), and J (joining) gene segments. In the RAG complex, RAG1 mediates the DNA-binding to the conserved recombination signal sequences (RSS) and catalyzes the DNA cleavage activities by introducing a double-strand break between the RSS and the adjacent coding segment. RAG2 is not a catalytic component but is required for all known catalytic activities. DNA cleavage occurs in 2 steps: a first nick is introduced in the top strand immediately upstream of the heptamer, generating a 3'-hydroxyl group that can attack the phosphodiester bond on the opposite strand in a direct transesterification reaction, thereby creating 4 DNA ends: 2 hairpin coding ends and 2 blunt, 5'-phosphorylated ends. The chromatin structure plays an essential role in the V(D)J recombination reactions and the presence of histone H3 trimethylated at 'Lys-4' (H3K4me3) stimulates both the nicking and haipinning steps. The RAG complex also plays a role in pre-B cell allelic exclusion, a process leading to expression of a single immunoglobulin heavy chain allele to enforce clonality and monospecific recognition by the B-cell antigen receptor (BCR) expressed on individual B lymphocytes. The introduction of DNA breaks by the RAG complex on one immunoglobulin allele induces ATM-dependent repositioning of the other allele to pericentromeric heterochromatin, preventing accessibility to the RAG complex and recombination of the second allele. In addition to its endonuclease activity, RAG1 also acts as a E3 ubiquitin-protein ligase that mediates monoubiquitination of histone H3. Histone H3 monoubiquitination is required for the joining step of V(D)J recombination. Mediates polyubiquitination of KPNA1.
Function:
Catalytic component of the RAG complex, a multiprotein complex that mediates the DNA cleavage phase during V(D)J recombination. V(D)J recombination assembles a diverse repertoire of immunoglobulin and T-cell receptor genes in developing B and T-lymphocytes through rearrangement of different V (variable), in some cases D (diversity), and J (joining) gene segments. In the RAG complex, RAG1 mediates the DNA-binding to the conserved recombination signal sequences (RSS) and catalyzes the DNA cleavage activities by introducing a double-strand break between the RSS and the adjacent coding segment. RAG2 is not a catalytic component but is required for all known catalytic activities. DNA cleavage occurs in 2 steps: a first nick is introduced in the top strand immediately upstream of the heptamer, generating a 3'-hydroxyl group that can attack the phosphodiester bond on the opposite strand in a direct transesterification reaction, thereby creating 4 DNA ends: 2 hairpin coding ends and 2 blunt, 5'-phosphorylated ends. The chromatin structure plays an essential role in the V(D)J recombination reactions and the presence of histone H3 trimethylated at 'Lys-4' (H3K4me3) stimulates both the nicking and haipinning steps. The RAG complex also plays a role in pre-B cell allelic exclusion, a process leading to expression of a single immunoglobulin heavy chain allele to enforce clonality and monospecific recognition by the B-cell antigen receptor (BCR) expressed on individual B-lymphocytes. The introduction of DNA breaks by the RAG complex on one immunoglobulin allele induces ATM-dependent repositioning of the other allele to pericentromeric heterochromatin, preventing accessibility to the RAG complex and recombination of the second allele. In addition to its endonuclease activity, RAG1 also acts as a E3 ubiquitin-protein ligase that mediates monoubiquitination of histone H3. Histone H3 monoubiquitination is required for the joining step of V(D)J recombination. Mediates polyubiquitination of KPNA1.
Subunit:
Homodimer. Component of the RAG complex composed of core components RAG1 and RAG2, and associated component HMGB1 or HMGB2.
Subcellular Location:
Nucleus.
Tissue Specificity:
Maturing lymphoid cells.
Post-translational modifications:
Autoubiquitinated in the presence of CDC34/UBCH3.
DISEASE:
Defects in RAG1 are a cause of combined cellular and humoral immune defects with granulomas (CHIDG) [MIM:233650]. CHIDG is an immunodeficiency disease with granulomas in the skin, mucous membranes, and internal organs. Other characteristics include hypogammaglobulinemia, a diminished number of T and B-cells, and sparse thymic tissue on ultrasonography.
Defects in RAG1 are a cause of severe combined immunodeficiency autosomal recessive T-cell-negative/B-cell-negative/NK-cell-positive (T(-)B(-)NK(+) SCID) [MIM:601457]. A form of severe combined immunodeficiency (SCID), a genetically and clinically heterogeneous group of rare congenital disorders characterized by impairment of both humoral and cell-mediated immunity, leukopenia, and low or absent antibody levels. Patients present in infancy recurrent, persistent infections by opportunistic organisms. The common characteristic of all types of SCID is absence of T-cell-mediated cellular immunity due to a defect in T-cell development.
Defects in RAG1 are a cause of Omenn syndrome (OS) [MIM:603554]. OS is a severe immunodeficiency characterized by the presence of activated, anergic, oligoclonal T-cells, hypereosinophilia, and high IgE levels.
Defects in RAG1 are the cause of alpha/beta T-cell lymphopenia with gamma/delta T-cell expansion severe cytomegalovirus infection and autoimmunity (T-CMVA) [MIM:609889]. An immunological disorder characterized by oligoclonal expansion of TCR gamma/delta T-cells, TCR alpha/beta T-cell lymphopenia, severe, disseminated cytomegalovirus infection and autoimmune cytopenia.
Similarity:
Belongs to the RAG1 family.
Contains 1 NBD (nonamer binding) DNA-binding domain.
Contains 1 RAG1-type zinc finger.
Contains 1 RING-type zinc finger.
SWISS:
P15918
Gene ID:
5896
抗体选择指南
RNF74抗体检测任何目的靶蛋白都有不止一种抗体可供选择，为缩小抗体的选择范围选中合适的抗体，需要考虑如下几种因素：
（1） 分析或应用的类型
（2）样本蛋白的结构性质
（3）样本的种属
（4）抗体宿主的种类
（5）抗体的标记和检测
1 分析试验的应用类型一般抗体说明书都列出该抗体经试验验证过适用于何种分析类型，如：
可以应用于WB IHC ICC ELASA 分析等，如果抗体说明书没有提及的应用类型，并不意味着该抗体不适用于此种分析应用类型，而仅是说明尚未经过此种分析试验验证，如果抗体不适用某些分析试验，则会在抗体说明书上标注出来不适于某分析试验。
2 样本蛋白的结构性质了解样本蛋白的结构性质有助于选择*合适的抗体，至少需要考虑两方面因素
(1)..待测样本蛋白的结构域：RNF74抗体是由各种不同**原**宿主而制备得来，其中的**原包括：全长蛋白、蛋白片断、多肽、全有机体（如：**）或细胞，抗体说明书一般都有**原的描述，如果打算检测的是蛋白片断或一种特殊的同型物或蛋白全长的某一区域，则必须选择用含此片段域的**原制备出的抗体。如果打算用FACS 流式检测活细胞的表面蛋白，则需要选择含该表面蛋白的胞外域来**制备的抗体。
(2)样本的提取或处理过程：某些抗体要求样本经过某些特殊处理，例如：许多抗体只识别还原和变性的、表位已暴露不受二级四级结构阻碍的蛋白样本，另一方面，某些抗体仅识别天然折迭状态的蛋白。
当选择**组化的抗体时，应注意某些抗体只识别未固定的冷冻的组织，而另一些抗体则适用于无需抗原修复解交联步聚的甲醛固定石蜡包埋的组织，这些都会在抗体说明书上应用部分标示出来 3 样本的物种 应选择物种相同或有交叉反应的抗体，抗体可能与不同物种的同种靶蛋白有交叉反应，因其氨基酸序列同源性较高。
如果样本的种类未列入抗体说明书上的交叉反应种属表中，并不意味着该抗体不适用于检测该物种的蛋白，而只是表示该物种尚未用此抗体检测验证过，应通过序列比对的方法来预测交叉反应，RNF74抗体可应用Expasy 和 NCBI BLAST 来进行不同物种蛋白同源性比对。
4 一抗宿主物种的选择一般说来，在使用偶联二抗结合无偶联物的一抗时，一抗宿主动物的物种选择较为重要，对于**组化而言，尽可能选择与样本不同种系物种的一抗，从而避免二抗与样本内源性**球蛋白产生交叉反应，
例如：检测小鼠样本蛋白，则不应选择小鼠或大鼠源的一抗，*好选兔源的一抗，则二抗则可选择偶联了检测分子（酶、荧光素、生物素等）的抗兔IgG。如果选择有偶联物的一抗则不适用上述情况，除**组化外的其它对不含内源性**球蛋白样本的检测方法，则抗体宿主物种的影响不大，如对不含IgG 的细胞裂解物样本的western blotting检测。
尽管如此，RNF74抗体含有血清的组织裂解物和组织培养上清中含有**球蛋白，还原变性样本中含IgG，在western blot 检测中则结合出现IgG 分子50 and 25 kDa 的重链和轻链条带。
5 二抗的选择 二抗应选用与使用的一抗相同的物种来源，例如：如果你的一抗是小鼠的单克隆抗体，二抗则选抗小鼠的二抗anti-mouse secondary。建议检查二抗说明书确保该抗体适用于你的检测应用， 二抗一般连接荧光素FITC 或发光团。
6 双重染色抗体的选择用未偶联一抗进行细胞培养物或组织切片的双重**染色要求一抗来源于不同物种并且二抗分别识别其中之一，二抗说明书应描述其与其它物种来源的**球蛋有否有交叉吸附。
合格 REA B**细胞受体相关蛋白抗体
合格 合格 COMP 软骨寡聚基质蛋白抗体
合格 C5R1 补体成分5受体1抗体
合格 Cytokeratin 19 细胞角蛋白19抗体
合格 TREM1 髓系细胞触发受体1抗体
合格 Cenexin1 精子尾部结构蛋白抗体
合格 CD22 B**细胞粘附分子CD22抗体
合格 VNN1 血管非炎症分子1抗体
合格 IFITM1 干扰素诱导跨膜蛋白1抗体
合格 phospho-HDAC4 (Ser632) 磷酸化组蛋白去乙酰化酶4抗体
合格 Inhibin Alpha 抑制素A/Inhibin α抗体
合格 Factor XII light chain 凝血因子12轻链抗体
合格 Factor I heavy chain 补体因子I重链抗体
合格 KRAS 原癌基因K-ras抗体
合格 AMPK alpha-1 腺苷单磷酸活化蛋白激酶α1/AMPK α 1抗体
合格 CD19 CD19抗体
合格 合格 CD86 CD86抗体
合格 TPOR 血小板生成素受体抗体
合格 LPA2 溶血磷脂酸受体蛋白2抗体
合格 合格 CD62L L选择素抗体
合格 Galectin-3 半乳糖凝集素3抗体
合格 合格 GLUT2 葡萄糖转运蛋白2抗体
合格 DCP 异常凝血酶原/脱-γ-羧基凝血酶原抗体
合格 Phospho-Smad1 (Ser463) 磷酸化细胞信号转导分子Smad-1抗体